Zura Bio Ltd 8-K

What Happened

• Zura Bio Ltd (ZURA) announced a priced public offering (filed on Form 8‑K). On February 24, 2026 the company agreed to sell 18,200,000 Class A ordinary shares at $6.25 per share and pre‑funded warrants to purchase 1,800,000 ordinary shares at $6.249 per warrant (exercise price $0.001). The underwriters—Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co.—had a 30‑day option for an additional 3,000,000 ordinary shares, which was exercised in full on February 25, 2026. The offering is being made under an effective Form S‑3 registration (No. 333‑281905) and was expected to close on February 26, 2026, subject to customary conditions.
• The company expects net proceeds of approximately $134.6 million after underwriting discounts, commissions and estimated offering expenses. The pre‑funded warrants are exercisable immediately, subject to ownership limits described below. Zura issued press releases on February 24 (launch) and February 25 (pricing) announcing the offering.

Key Details

• Offering size (initial): 18,200,000 ordinary shares + 1,800,000 pre‑funded warrants; additional 3,000,000 shares added via underwriter option (exercised).
• Public price: $6.25 per ordinary share; $6.249 per pre‑funded warrant (reflecting a $0.001 exercise price).
• Expected net proceeds: approximately $134.6 million.
• Preliminary cash position: approximately $109.4 million in cash and cash equivalents as of December 31, 2025 (unaudited, preliminary figure). Outstanding shares after the offering: 94,875,460 (assuming no exercise of pre‑funded warrants).

Why It Matters

• Capital and dilution: The offering provides Zura with a meaningful cash infusion (expected ~$134.6M), which increases the company’s liquidity beyond the reported preliminary $109.4M cash balance as of year‑end. At the same time, the issuance increases the outstanding share count (reported post‑offering figure: 94,875,460, assuming no warrant exercises), which dilutes existing shareholders.
• Timing and limits: The pre‑funded warrants can be exercised immediately (exercise price $0.001), but individual holders are subject to a default beneficial ownership cap of 9.99% (can be increased to up to 19.99% with 61 days’ notice), which can affect large investors’ immediate ownership. The offering was priced and the underwriter option was fully exercised in late February 2026, with anticipated closing subject to customary conditions.
• Risk note: The company’s cash figure is preliminary and unaudited and the offering-related outcomes depend on customary closing conditions. Zura’s filings include standard forward‑looking disclaimers.